Fate Therapeutics to Present at Upcoming February Investor Conferences
Fate Therapeutics, a clinical-stage biopharmaceutical firm focused on cellular immunotherapies for cancer, announced upcoming presentations at two investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Fate Therapeutics, a clinical-stage biopharmaceutical firm focused on cellular immunotherapies for cancer, announced upcoming presentations at two investor conferences. The 4th Annual Guggenheim Oncology Day will take place on February 9, 2022, at 11:00 AM ET, followed by the SVB Leerink 2022 Global Healthcare Conference on February 16, 2022, at 3:00 PM ET. Webcasts of these events will be available in the Investors section on their website.
Fate Therapeutics develops universal, off-the-shelf cell therapies using its proprietary iPSC platform.
Details
News Market Reaction – FATE
The recorded move for FATE in the trading session of this news was -3.70%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company will present at the following upcoming investor conferences:
- 4th Annual Guggenheim Oncology Day available on demand on Wednesday, February 9, 2022 at 11:00 AM ET
- SVB Leerink 2022 Global Healthcare Conference on demand on Wednesday, February 16, 2022 at 3:00 PM ET
A live webcast, if recorded, of each presentation can be accessed under “Events & Presentations” in the Investors section of the Company’s website at www.fatetherapeutics.com. The archived webcast will be available on the Company’s website shortly after the event.
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company’s immuno-oncology pipeline includes off-the-shelf, iPSC-derived natural killer (NK) cell and T-cell product candidates, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens using chimeric antigen receptors (CARs). Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
Contact:
Christina Tartaglia
Stern Investor Relations, Inc.
212.362.1200
christina@sternir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.